Search

ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).

This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.

Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.

In this personal interview, we speak to ProQR’s Chief Corporate Development Officer & General Counsel, René Beukema on his return to ProQR.

Throughout the year ProQR regularly welcomes student groups from across the Netherlands.

Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.

He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.